1-43431066-C-T

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2

The NM_001365999.1(SZT2):​c.4892C>T​(p.Thr1631Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000233 in 1,613,896 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. T1631T) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.00014 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00024 ( 2 hom. )

Consequence

SZT2
NM_001365999.1 missense

Scores

18

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:3B:3

Conservation

PhyloP100: 3.10

Publications

4 publications found
Variant links:
Genes affected
SZT2 (HGNC:29040): (SZT2 subunit of KICSTOR complex) The protein encoded by this gene is expressed in the brain, predominantly in the parietal and frontal cortex as well as in dorsal root ganglia. It is localized to the peroxisome, and is implicated in resistance to oxidative stress. It likely functions by increasing superoxide dismutase (SOD) activity, but itself has no direct SOD activity. Studies in mice show that this gene confers low seizure threshold, and may also enhance epileptogenesis. [provided by RefSeq, Jun 2011]
SZT2 Gene-Disease associations (from GenCC):
  • developmental and epileptic encephalopathy, 18
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P, Illumina
  • genetic developmental and epileptic encephalopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • undetermined early-onset epileptic encephalopathy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.007987797).
BP6
Variant 1-43431066-C-T is Benign according to our data. Variant chr1-43431066-C-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 411931.
BS2
High Homozygotes in GnomAdExome4 at 2 AR,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SZT2NM_001365999.1 linkc.4892C>T p.Thr1631Met missense_variant Exon 33 of 72 ENST00000634258.3 NP_001352928.1
SZT2NM_015284.4 linkc.4721C>T p.Thr1574Met missense_variant Exon 32 of 71 NP_056099.3 Q5T011-5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SZT2ENST00000634258.3 linkc.4892C>T p.Thr1631Met missense_variant Exon 33 of 72 5 NM_001365999.1 ENSP00000489255.1 Q5T011-1
SZT2ENST00000562955.2 linkc.4721C>T p.Thr1574Met missense_variant Exon 32 of 71 5 ENSP00000457168.1 Q5T011-5
SZT2ENST00000648058.1 linkn.32C>T non_coding_transcript_exon_variant Exon 1 of 40
SZT2ENST00000638642.1 linkn.-65C>T upstream_gene_variant 3

Frequencies

GnomAD3 genomes
AF:
0.000145
AC:
22
AN:
152114
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00166
Gnomad FIN
AF:
0.0000942
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000162
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000442
AC:
111
AN:
251138
AF XY:
0.000516
show subpopulations
Gnomad AFR exome
AF:
0.000123
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000185
Gnomad NFE exome
AF:
0.000185
Gnomad OTH exome
AF:
0.000653
GnomAD4 exome
AF:
0.000242
AC:
354
AN:
1461664
Hom.:
2
Cov.:
32
AF XY:
0.000314
AC XY:
228
AN XY:
727142
show subpopulations
African (AFR)
AF:
0.000149
AC:
5
AN:
33476
American (AMR)
AF:
0.0000224
AC:
1
AN:
44676
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26120
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00209
AC:
180
AN:
86216
European-Finnish (FIN)
AF:
0.0000187
AC:
1
AN:
53398
Middle Eastern (MID)
AF:
0.00225
AC:
13
AN:
5768
European-Non Finnish (NFE)
AF:
0.000118
AC:
131
AN:
1111920
Other (OTH)
AF:
0.000381
AC:
23
AN:
60390
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.487
Heterozygous variant carriers
0
20
39
59
78
98
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000145
AC:
22
AN:
152232
Hom.:
0
Cov.:
32
AF XY:
0.000121
AC XY:
9
AN XY:
74430
show subpopulations
African (AFR)
AF:
0.0000482
AC:
2
AN:
41534
American (AMR)
AF:
0.00
AC:
0
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5168
South Asian (SAS)
AF:
0.00166
AC:
8
AN:
4810
European-Finnish (FIN)
AF:
0.0000942
AC:
1
AN:
10620
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000162
AC:
11
AN:
68018
Other (OTH)
AF:
0.00
AC:
0
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
2
4
5
7
9
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000139
Hom.:
0
Bravo
AF:
0.000125
ExAC
AF:
0.000404
AC:
49
EpiCase
AF:
0.000273
EpiControl
AF:
0.000474

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:3
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Developmental and epileptic encephalopathy, 18 Uncertain:2
Jun 16, 2021
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

SZT2 NM_015284.3 exon 32 p.Thr1574Met (c.4721C>T): This variant has not been reported in the literature but is present in 0.01% (11/68026) of European alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/1-43431066-C-T?dataset=gnomad_r3). This variant is present in ClinVar (Variation ID:411931). This variant amino acid Methionine (Met) is present in >10 species and is not well conserved among evolutionarily distant species; this suggests that this variant may not impact the protein. Additional computational prediction tools do not suggest an impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. -

Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Jan 30, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 10, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Uncertain:1
Jun 06, 2019
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.T1574M variant (also known as c.4721C>T), located in coding exon 32 of the SZT2 gene, results from a C to T substitution at nucleotide position 4721. The threonine at codon 1574 is replaced by methionine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

SZT2-related disorder Benign:1
Apr 01, 2022
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.072
BayesDel_addAF
Benign
-0.57
T
BayesDel_noAF
Benign
-0.60
CADD
Benign
18
DANN
Benign
0.93
DEOGEN2
Benign
0.034
T;.
Eigen
Benign
-0.54
Eigen_PC
Benign
-0.42
FATHMM_MKL
Benign
0.61
D
LIST_S2
Benign
0.81
T;T
M_CAP
Benign
0.0026
T
MetaRNN
Benign
0.0080
T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.34
N;.
PhyloP100
3.1
PrimateAI
Benign
0.37
T
PROVEAN
Benign
-0.16
.;N
Sift
Benign
0.12
.;T
Sift4G
Benign
0.13
T;T
Polyphen
0.0030
.;B
Vest4
0.20
MVP
0.17
MPC
0.37
ClinPred
0.013
T
GERP RS
3.7
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.028
gMVP
0.32
Mutation Taster
=90/10
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs201312287; hg19: chr1-43896737; COSMIC: COSV65170542; COSMIC: COSV65170542; API